Skip to main content
SpringerLink
Log in

Economic implications of attention-deficit hyperactivity disorder for healthcare systems

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic conditions of childhood, with adverse consequences that persist through adolescence into adulthood. Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society at large. This article reviews available information about ADHD-associated utilisation of healthcare resources, direct medical costs, and the costs or cost effectiveness of pharmacological interventions.

Published estimates suggest that direct medical costs for youth with ADHD are approximately double those for youth without ADHD. Cross-sectional studies suggest that ADHD-associated incremental costs are highest for mental health services and pharmaceutical costs, and are greatest for youth with comorbid psychiatric conditions and for those being treated with stimulant medication. To guide relevant clinical and health policy, additional research is warranted on the following: source of increased costs observed among persons with ADHD; patient characteristics of those accruing high medical costs; and the long-term effect of ADHD treatment on direct and indirect costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Wokaich ML. Attention deficit hyperactivity disorder: the most studied and yet most controversial diagnosis. Ment Retard Dev Disabil Res Rev 1999; 5: 163–8

    Article  Google Scholar 

  2. Barbaresi W, Katusic SK, Colligan RC, et al. How common is attention-deficit/hyperactivity disorder?: incidence in a popu-lation-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med 2002; 156: 217–24

    PubMed  Google Scholar 

  3. Sawyer MG, Arney FM, Baghurst PA, et al. The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being. Aust N Z J Psychiatry 2001; 35: 806–14

    Article  PubMed  CAS  Google Scholar 

  4. Angold A, Erkanli A, Egger HL, et al. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 2000; 39: 975–84

    Article  PubMed  CAS  Google Scholar 

  5. Jensen PS, Kettle L, Roper MT, et al. Are stimulants over-prescribed?: treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 1999; 38: 797–804

    Article  PubMed  CAS  Google Scholar 

  6. Pineda D, Ardila A, Rossetti M, et al. Prevalence of attention-deficit/hyperactivity disorder symptoms in 4- to 17-year-old children in the general population. J Abnorm Child Psychol 1999; 27: 455–62

    Article  PubMed  CAS  Google Scholar 

  7. Rowland AS, Umbach DM, Catoe KE, et al. Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results. Can J Psychiatry 2001; 46: 931–40

    PubMed  CAS  Google Scholar 

  8. Wokaich ML, Hannah IN, Pinnock TY, et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996; 35: 319–24

    Article  Google Scholar 

  9. Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 1995; 34: 629–38

    Article  PubMed  CAS  Google Scholar 

  10. Abikoff HB, Jensen PS, Arnold LLE, et al. Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol 2002; 30: 349–59

    Article  PubMed  Google Scholar 

  11. Rohde LA, Biederman J, Busnello EA, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. J Am Acad Child Adolesc Psychiatry 1999; 38: 716–22

    Article  PubMed  CAS  Google Scholar 

  12. Brock SW, Knapp PK. Reading comprehension abilities of children with attention-deficit/hyperactivity disorder. J Allen Disord 1996; 1: 173–86

    Article  Google Scholar 

  13. Casey JE, Rourke BP, Del Dotto JE. Learning disabilities in children with attention deficit disorder with and without hyper-activity. Neuropsychol Dev Cogn Sect C Child Neuropsychol 1996; 2: 83–98

    Google Scholar 

  14. Barkley RA, Anastopoulos AD, Guevremont DC, et al. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization. J Am Acad Child Adolesc Psychiatry 1991, 61

    Google Scholar 

  15. Szatmari P, Offord DR, Boyle MIL. Correlates, associated im-pairments and patterns of service utilization of children with attention deficit disorder: findings from the Ontario Child Health Study. J Child Psychol Psychiatry 1989; 30: 205–17

    Article  PubMed  CAS  Google Scholar 

  16. Pope AW, Bierman KL, Mumma GH. Relations between hyper-active and aggressive behavior and peer relations at three elementary grade levels. J Abnorm Child Psychol 1989; 17: 253–67

    Article  PubMed  CAS  Google Scholar 

  17. Cantwell DP, Satterfield JH. The prevalence of academic under-achievement in hyperactive children. J Pediatr Psychol 1978; 3: 168–71

    Article  Google Scholar 

  18. Fischer M, Barkley RA, Smallish L, et al. Young adult followup of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002; 30: 463–75

    Article  PubMed  Google Scholar 

  19. Bagwell CL, Molina BS, Pelham Jr WE, et al. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 2001; 40: 1285–92

    Article  PubMed  CAS  Google Scholar 

  20. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 2000, 31

    Google Scholar 

  21. Hansen C, Weiss D, Last CG. ADHD boys in young adulthood: psychosocial adjustment. J Am Acad Child Adolesc Psychiatry 1999; 38: 165–71

    Article  PubMed  CAS  Google Scholar 

  22. Mannuzza S, Klein RG, Bessler A, et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155: 493–8

    PubMed  CAS  Google Scholar 

  23. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50: 565–76

    Article  PubMed  CAS  Google Scholar 

  24. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990; 29: 546–57

    Article  PubMed  CAS  Google Scholar 

  25. Fischer M, Barkley R, Fletcher K, et al. The adolescent outcome of hyperactive children diagnosed by research criteria. II: academic, attentional and neuropsychological status. J Consult Clin Psychol 1990; 58: 580–8

    Article  PubMed  CAS  Google Scholar 

  26. Greenfield B, Hechtman L, Weiss G. Two subgroups of hyper-actives as adults: correlations of outcome. Can J Psychiatry 1988; 33: 505–8

    PubMed  CAS  Google Scholar 

  27. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 71–8

    Article  PubMed  CAS  Google Scholar 

  28. Voigt RG, Barbaresi WJ, Colligan RC, et al. Occurrence of attention-deficit hyperactivity disorder (ADHD) among indi-viduals with and without mild mental retardation in a popula tion-based birth cohort [abstract]. J Dev Behav Pediatr 2001; 22: 349

    Article  Google Scholar 

  29. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry 2001; 42: 487–92

    Article  PubMed  CAS  Google Scholar 

  30. Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993; 32: 361–8

    Article  PubMed  CAS  Google Scholar 

  31. Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285: 60–6

    Article  PubMed  CAS  Google Scholar 

  32. Woodward LJ, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional difficulties in adolescence. J Am Acad Child Adolesc Psychiatry 2000; 39: 627–34

    Article  PubMed  CAS  Google Scholar 

  33. DiScala C, Lescohier I, Barthel M, et al. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998; 102: 1415–21

    Article  PubMed  CAS  Google Scholar 

  34. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with atten-tion deficit hyperactivity disorder. Pediatrics 1996; 98: 1089–95

    PubMed  CAS  Google Scholar 

  35. Lalloo R, Sheiham A. Risk factors for childhood major and minor head and other injuries in a nationally representative sample. Injury 2003; 34: 261–6

    Article  PubMed  Google Scholar 

  36. Sassi F, Archard L, McDaid D. Searching literature databases for health care economic evaluations: how systematic can we afford to be? Med Care 2002; 40: 387–94

    Article  PubMed  Google Scholar 

  37. Kelleher KJ, McInemy TK, Gardner WP, et al. Increasing identification of psychosocial problems: 1979-1996. Pediatrics 2000; 105: 1313–21

    Article  PubMed  CAS  Google Scholar 

  38. Hoagwood K, Kelleher KJ, Feil M, et al. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry 2000; 39: 198–206

    Article  PubMed  CAS  Google Scholar 

  39. Rushton J, Bruckman D, Kelleher K. Primary care referral of children with psychosocial problems. Arch Pediatr Adolesc Med 2002; 156: 592–8

    PubMed  Google Scholar 

  40. Robison LM, Skaer TL, Sclar DA, et al. Is attention deficit hyperactivity disorder increasing among girls in the US?: trends in the diagnosis and the prescribing of stimulants. CNS Drugs 2002; 16: 129–37

    Article  PubMed  Google Scholar 

  41. Zito JM, Safer DJ, dosReis S, et al. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Arch Pediatr Med 1999; 153: 1257–63

    Article  CAS  Google Scholar 

  42. Pastor PN, Reuben C. Attention deficit hyperactivity disorder and learning disability: United States, 1997–98. National Center for Health Statistics Vital and Health Statistics 2002 Series 206, Number 206. Poster presented at the Academy for Health Services Research and Health Policy Annual Research Meeting; 2002 Jun 23–25; Washington, D.C

    Google Scholar 

  43. Bussing R, Zima BT, Perwien AR, et al. Children in special education programs: attention deficit hyperactivity disorder, use of services, and unmet needs. Am J Public Health 1998; 88: 880–6

    Article  PubMed  CAS  Google Scholar 

  44. Miller AR, Lalonde CE, McGrail KM, et al. Prescription of methylphenidate to children and youth: 1990–1996. CMAJ 2001; 165: 1505–6

    Google Scholar 

  45. Brownell MD, Yogendran MS. Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychos_ timulant treatment rates. Can J Psychiatry 2001; 46: 264–72

    PubMed  CAS  Google Scholar 

  46. Fogelman Y, Kahan E. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel: a controversial issue. Isr Med Assoc J 2001; 3: 925–7

    PubMed  CAS  Google Scholar 

  47. Schirm E, Tobi H, Zito JM, et al. Psychotropic medication in children: a study from the Netherlands [abstract]. Pediatrics 2001; 108: E25

    Article  PubMed  CAS  Google Scholar 

  48. Reid R, Hakendof P, Prosser B. Use of psychostimulant medication for ADHD in South Australia. J Am Acad Child Adolesc Psychiatry 2002; 41: 906–13

    Article  PubMed  Google Scholar 

  49. Safer DJ, Malever M. Stimulant treatment in Maryland public schools. Pediatrics 2000; 106: 533–9

    Article  PubMed  CAS  Google Scholar 

  50. Rowland AS, Umbach DM, Stallone L, et al. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health 2002; 92: 231–4

    Article  PubMed  Google Scholar 

  51. Rushton JL, Whitmire IT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends 1992 to 1998. Arch Pediatr Adolesc Med 2001; 155: 560–5

    PubMed  CAS  Google Scholar 

  52. Leslie DL, Rosenheck RA, Horwitz SM. Patterns of mental health utilization and costs among children in a privately insured population. Health Serv Res 2001; 36: 113–27

    PubMed  CAS  Google Scholar 

  53. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the Medical Expenditure Panel Survey. Arch Pediatr Adolesc Med 2002; 156: 504–11

    PubMed  Google Scholar 

  54. Kelleher KJ, Childs GE, Harman IS. Healthcare costs for children with attention-deficit hyperactivity disorder. Econ Neurosci 2001; 3: 60–3

    Google Scholar 

  55. National Institutes of Health CDC. Diagnosis and treatment of attention deficit hyperactivity disorder. NIH Consensus Statement, 1998 [online] Available from URL: http://odp.od.nih.gov/consensus/cons/110/110statement.htm. [Accessed 2002 Nov]

  56. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J Am Acad Child Adolesc Psychiatry 1997; 36: 85S–121S

    Article  Google Scholar 

  57. Zwillich T. Mental health benefits slashed over past decade. Clin Psychiatry News 1998; 26: 1–2

    Google Scholar 

  58. Zwillich T. Mental health benefits continue 10-year decline. Clin Psychiatry News 1999; 27: 31

    Google Scholar 

  59. Agency for Health Care Research and Quality. What is MEPS? [online]. Available from URL: http://www.meps.ahrq.gov/WhatIsMEPS/Overview.HTM [Accessed 2002 Nov]

  60. Katusic SK, Colligan RC, Barbaresi WJ, et al. Potential influence of migration bias in birth cohort studies. Mayo Clin Proc 1998; 73: 1053–61

    Article  PubMed  CAS  Google Scholar 

  61. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  62. Melton III LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 266–74

    Article  PubMed  Google Scholar 

  63. Miller A, Lee SK, Raina P. Part 1: overview and clinical evaluation of the use of methylphenidate for attention-deficit/ hyperactivity disorder. In: Miller A, Lee SK, Raina P, et al., editors. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998

    Google Scholar 

  64. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  65. Shaffer D, Schwab-Stone M, Fisher P, et al. The diagnostic interview schedule for children-revised versions (DISC-R): preparation, field testing, interrater reliability, and acceptability. J Am Acad Child Adolesc Psychiatry 1993; 32: 643–50

    Article  PubMed  CAS  Google Scholar 

  66. Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder [abstract]. Pediatrics 2002; 109: E39

    Article  PubMed  Google Scholar 

  67. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001; 22: 60–73

    Article  PubMed  CAS  Google Scholar 

  68. James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40: 1268–76

    Article  PubMed  CAS  Google Scholar 

  69. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001; 23: 1904–21

    Article  PubMed  CAS  Google Scholar 

  70. Schachter HM, Pham BA, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? CMAJ 2001; 165: 1475–88

    PubMed  CAS  Google Scholar 

  71. Jadad AR, Boyle M, Cunningham C, et al. Treatment of Attention deficit/ hyperactivity disorder: evidence report/technology assessment (summary). Rockville (MD): Agency for Healthcare Research and Quality, 1999: 1–341

    Google Scholar 

  72. Klassen A, Miller A, Raina P, et al. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999; 44: 1007–16

    PubMed  CAS  Google Scholar 

  73. Gillberg C, Melander H, von Knotting AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857–64

    Article  PubMed  CAS  Google Scholar 

  74. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100: 662–6

    Article  PubMed  CAS  Google Scholar 

  75. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001; 10: 85–94

    Article  PubMed  CAS  Google Scholar 

  76. Zupancic JAF, Miller A, Raina P, et al. Part 3: economic evaluation of pharmaceutical and psychological/ behavioral therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Raina P, et al., editors. A review of therapies for attention-deficit/hyperactivity disorder [online]. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998. Available from URL: http://www.ecohta.ca/publications/pdf/adhd-techrep.pdf [Accessed 2003 Oct 16]

    Google Scholar 

  77. Rosser R, Cottee M, Rabin R, et al. Index of health related quality of life. In: Hopkins A, editor. Measures of the quality of life, and the uses to which they may be put. London: Royal College of Physicians of London, 1992: 81–89

    Google Scholar 

  78. Shukla VK, Otten N. Assessment of attention deficit/hyperactivity disorder therapy: a Canadian perspective [online]. Available at URL: http://www.ecohta.ca/publications/pdf/overadhdeng.pdf [Accessed: 2002 Nov]

  79. Conners CK. Manual for Conners’ rating scales. Toronto, Canada: Multi-Health Systems Inc, 1989

    Google Scholar 

  80. Hoagwood K, Jensen PS, Feil M, et al. Medication management of stimulants in pediatric practice settings: a national perspective. J Dev Behav Pediatr 2000; 21: 322–31

    Article  PubMed  CAS  Google Scholar 

  81. Rushton JL, Felt BT, Roberts MW. Coding of pediatric behavioral and mental disorders [online]. Available from URL: blip://wwwpediatries.org/egi/content/full/110/l/e8. [Accessed 2002 Nov]

  82. Mannuzza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997; 36: 1222–7

    Article  PubMed  CAS  Google Scholar 

  83. Weiss G, Hechtman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985; 24: 211–20

    Article  PubMed  CAS  Google Scholar 

  84. Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Psychiatry 1984; 23: 261–9

    Article  PubMed  CAS  Google Scholar 

  85. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998; 31: 533–44

    Article  PubMed  CAS  Google Scholar 

  86. Fergusson DM, Lynskey MT, Horwood LJ. Attentional difficulties in middle childhood and psychosocial outcomes in young adulthood. J Child Psychol Psychiatry 1997; 38: 633–44

    Article  PubMed  CAS  Google Scholar 

  87. Schaughency E, McGee R, Raja SN, et al. Self-reported inatten-tion, impulsivity, and hyperactivity at ages 15 and 18 years in the general population. J Am Acad Child Adolesc Psychiatry 1994; 33: 173–84

    Article  PubMed  CAS  Google Scholar 

  88. Wilens TE, Famone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?: a meta-analytic review of the literature. Pediatrics 2003; 111: 179–85

    Article  PubMed  Google Scholar 

  89. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder [abstract]. Pediatrics 1999; 104: e20

    Article  PubMed  CAS  Google Scholar 

  90. Earle CC, Tsai IS, Gelber RD, et al. Effectiveness of chemo-therapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001; 19: 1064–70

    PubMed  CAS  Google Scholar 

  91. McClellan MB, Newhouse JP. Instrumental variables analysis applications in health services research: a special supplement to HSR. Health Serv Res 2000; 35: 1061–202

    PubMed  CAS  Google Scholar 

  92. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150: 327–33

    Article  PubMed  CAS  Google Scholar 

  93. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using a subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516–24

    Article  Google Scholar 

  94. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461–94

    Article  PubMed  CAS  Google Scholar 

  95. Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Methodol 2000; 1: 185–202

    Article  Google Scholar 

  96. Mrazek DA. A crisis in child psychiatric service delivery: why hasn’t the piper been paid? Mayo Clin Proc 2001; 76: 1078–80

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Drs Slavica Katusic and William Barbaresi for their helpful reviews and comments. Dr Leibson is funded in part by McNeil Consumer and Specialty Pharmaceuticals. The authors have provided no information on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Health Sciences Research, Mayo Clinic Foundation, 200 1st Street SW, Rochester, Minnesota, 55905, USA

    Cynthia L. Leibson & Kirsten Hall Long

Authors
  1. Cynthia L. Leibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kirsten Hall Long
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia L. Leibson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leibson, C.L., Long, K.H. Economic implications of attention-deficit hyperactivity disorder for healthcare systems. Pharmacoeconomic 21, 1239–1262 (2003). https://doi.org/10.2165/00019053-200321170-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321170-00002

Keywords

Search

Navigation